CPI-0610

CPI-0610
Identifiers
	IUPAC name 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide;
CAS Number	1380087-89-7;
PubChem CID	57389999;
ChemSpider	32738784;
UNII	U4017GUQ06;
ChEBI	CHEBI:189653;
CompTox Dashboard (EPA)	DTXSID201022544 ;
Chemical and physical data
Formula	C20H16ClN3O2
Molar mass	365.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl;
	InChI InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1; Key:GCWIQUVXWZWCLE-INIZCTEOSA-N;

CPI-0610 is a drug which acts as a BET inhibitor, mainly acting at the BRD2 and BRD4 subtypes. It has potential applications in the treatment of various forms of cancer.^[1]^[2]^[3]^[4]

References

^ Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Côté A, Leblanc Y, et al. (February 2016). "Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials". Journal of Medicinal Chemistry. 59 (4): 1330–9. doi:10.1021/acs.jmedchem.5b01882. PMID 26815195.
^ Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS (January 2019). "Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma". Neoplasia. 21 (1): 82–92. doi:10.1016/j.neo.2018.11.006. PMC 6280696. PMID 30529073.
^ Raythatha J, Arnold L (November 2019). "The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis". Epigenomics. 11 (14): 1553–1555. doi:10.2217/epi-2019-0274. PMID 31729905.
^ Bankar A, Gupta V (April 2020). "Investigational non-JAK inhibitors for chronic phase myelofibrosis". Expert Opinion on Investigational Drugs. 29 (5): 461–474. doi:10.1080/13543784.2020.1751121. PMID 32245330.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Côté A, Leblanc Y, et al. (February 2016). "Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials". Journal of Medicinal Chemistry. 59 (4): 1330–9. doi:10.1021/acs.jmedchem.5b01882. PMID 26815195.

[2] Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS (January 2019). "Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma". Neoplasia. 21 (1): 82–92. doi:10.1016/j.neo.2018.11.006. PMC 6280696. PMID 30529073.

[3] Raythatha J, Arnold L (November 2019). "The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis". Epigenomics. 11 (14): 1553–1555. doi:10.2217/epi-2019-0274. PMID 31729905.

[4] Bankar A, Gupta V (April 2020). "Investigational non-JAK inhibitors for chronic phase myelofibrosis". Expert Opinion on Investigational Drugs. 29 (5): 461–474. doi:10.1080/13543784.2020.1751121. PMID 32245330.

[1]

[2]

[3]

[4]